Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 14, 2025
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) and issuance of a Convertible Promissory Note.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Principal Amount: $33,000
- Purchase Price (Net Proceeds): $30,000
- Interest Rate: 8% per annum
- Maturity Date: November 11, 2025
- Intended Use of Proceeds: General working capital
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt levels outside of this specific note.
Material Changes and Transaction Terms
The Company entered into a private placement for a convertible note with the following material terms:
- Conversion Price: Fixed at $6.00 per share. However, if the Common Stock trades below $5.00 for more than five consecutive trading days, the price adjusts to $3.00 per share.
- Default Conversion: In the event of default, the conversion price becomes the lowest trading price of the Common Stock on the OTC Markets.
- Prepayment Penalties:
- First 60 days: 110% of face amount plus accrued interest.
- Days 61-120: 120% of face amount plus accrued interest.
- Days 121-180: 125% of face amount plus accrued interest.
- After 180 days: No right to prepay.
- Ownership Limitation: Conversions are subject to a 4.99% beneficial ownership limitation.
- Reserve Requirement: The Company must maintain an initial reserve of at least 500% of the number of Conversion Shares.
Guidance, Risks, and Contingencies
Events of Default: The Note includes specific triggers for immediate repayment, including:
- Failure to pay principal or interest when due.
- Failure to timely issue Conversion Shares.
- Failure to maintain listing on an OTC market or equivalent exchange.
- Failure to comply with SEC reporting requirements.
- Insolvency, bankruptcy, or liquidation.
Regulatory Status: The securities were issued pursuant to the private placement exemption under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D. The filing does not contain forward-looking guidance or management commentary regarding future operational performance.
Investor Verification Checklist
- Verify the Company's current stock price relative to the $5.00 threshold that triggers a conversion price reduction to $3.00.
- Confirm the Company's ability to maintain its OTC listing status to avoid an event of default.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 4.1) for additional covenants.
- Assess the dilution impact of the 500% reserve requirement on existing shareholders.
- Monitor the Company's compliance with SEC reporting requirements to prevent default.